Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/19/2021 02/22/2021 02/23/2021 02/24/2021 02/25/2021 Date
74.31(c) 74.93(c) 74.54(c) 74.57(c) 74.62(c) Last
11 820 807 8 217 998 10 401 224 9 388 197 10 407 384 Volume
-1.46% +0.83% -0.52% +0.04% +0.07% Change
More quotes
Financials (USD)
Sales 2020 48 177 M - -
Net income 2020 12 094 M - -
Net Debt 2020 15 823 M - -
P/E ratio 2020 15,8x
Yield 2020 3,24%
Sales 2021 51 982 M - -
Net income 2021 14 500 M - -
Net Debt 2021 15 078 M - -
P/E ratio 2021 13,9x
Yield 2021 3,40%
Capitalization 189 B 189 B -
EV / Sales 2020 4,25x
EV / Sales 2021 3,92x
Nbr of Employees 71 000
Free-Float 70,7%
More Financials
Company
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or... 
Sector
Pharmaceuticals
Calendar
03/12Ex-dividend day for
More about the company
Notations Surperformance© of Merck & Co., Inc.
Trading Rating : Investor Rating :
More Ratings
All news about MERCK & CO., INC.
02/25MERCK : & CO., INC. Management's Discussion and Analysis of Financial Condition ..
AQ
02/25MERCK : Animal Health Completes Acquisition of Poultry Sense Limited
BU
02/25SECTOR UPDATE : Health Care Stocks Fall Thursday but Mostly Resist Steep Slide
MT
02/25SHAREHOLDER ALERT : WeissLaw LLP Investigates Pandion Therapeutics, Inc.
PR
02/25SECTOR UPDATE : Health Care Stocks Starting to Lose More Ground This Afternoon
MT
02/25JPMorgan CEO of Chase consumer banking leaving to head TIAA
RE
02/25GLOBAL MARKETS LIVE: Moderna, Best Buy, Nvidia…
02/25SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday
MT
02/25PANDION THERAPEUTICS : Shares More Than Double Premarket on Takeover by Merck
DJ
02/25MERCK : to Buy Pandion Therapeutics for $1.85 Billion
DJ
02/25Merck to Acquire Pandion Therapeutics for $1.85 Billion in All-Cash Deal
MT
02/25MERCK : to Acquire Pandion Therapeutics
BU
02/24MERCK : to Present at the Cowen 41st Annual Health Care Conference
BU
02/18MERCK : AstraZeneca - Independent Data Monitoring Committee Concludes OlympiA Tr..
AQ
02/17Stocks End Mixed After Strong Retail Sales Report; Verizon, Chevron Lift Dow ..
MT
More news
News in other languages on MERCK & CO., INC.
02/25MÄRKTE USA/Rentenmarkt schickt Wall Street auf Talfahrt
02/25MÄRKTE USA/Steigende Renditen schicken Wall Street auf Talfahhrt
02/25MÄRKTE USA/Abgaben trotz guter US-Daten - Gamestop im Blick
02/25Les valeurs à suivre aujourd'hui à Wall Street Jeudi 25 février 2021
02/25MERCK : acquiert la biotech Pandion pour près de deux milliards de dollars
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Stock Trading Strategies
MERCK & CO., INC - 2020
Good timing to go long again
BUY
More Stock Trading Analysis
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 96,76 $
Last Close Price 74,62 $
Spread / Highest target 43,4%
Spread / Average Target 29,7%
Spread / Lowest Target 5,87%
EPS Revisions
Managers and Directors
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-8.78%188 791
JOHNSON & JOHNSON3.42%427 844
ROCHE HOLDING AG-3.87%281 904
NOVARTIS AG-5.51%197 388
ABBVIE INC.0.17%189 532
PFIZER INC.-8.31%188 042